Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-arm, Open-label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed While Receiving HER2-Directed Therapy

NCT00509769 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00509769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00509769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-arm, Open-label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed While Receiving HER2-Directed Therapy
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
June 30, 2009
Enrollment
112 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer